AU2020235263A1 - Antibodies targeting C5aR - Google Patents

Antibodies targeting C5aR Download PDF

Info

Publication number
AU2020235263A1
AU2020235263A1 AU2020235263A AU2020235263A AU2020235263A1 AU 2020235263 A1 AU2020235263 A1 AU 2020235263A1 AU 2020235263 A AU2020235263 A AU 2020235263A AU 2020235263 A AU2020235263 A AU 2020235263A AU 2020235263 A1 AU2020235263 A1 AU 2020235263A1
Authority
AU
Australia
Prior art keywords
seq
antibody
region
human
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020235263A
Other languages
English (en)
Inventor
Barbara BACHLER-KONETZKI
Winfried Elis
Tanja Herrmann
Julia Neugebauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of AU2020235263A1 publication Critical patent/AU2020235263A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2020235263A 2019-03-14 2020-03-13 Antibodies targeting C5aR Pending AU2020235263A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19162759 2019-03-14
EP19162759.5 2019-03-14
PCT/EP2020/056754 WO2020182974A1 (en) 2019-03-14 2020-03-13 Antibodies targeting c5ar

Publications (1)

Publication Number Publication Date
AU2020235263A1 true AU2020235263A1 (en) 2021-09-02

Family

ID=65812165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020235263A Pending AU2020235263A1 (en) 2019-03-14 2020-03-13 Antibodies targeting C5aR

Country Status (14)

Country Link
US (3) US20220135658A1 (https=)
EP (1) EP3938393A1 (https=)
JP (2) JP7617012B2 (https=)
KR (1) KR20210141988A (https=)
CN (1) CN113574072B (https=)
AU (1) AU2020235263A1 (https=)
BR (1) BR112021017860A2 (https=)
CA (1) CA3132771A1 (https=)
IL (1) IL286238A (https=)
MA (1) MA55285A (https=)
MX (1) MX2021011040A (https=)
SG (1) SG11202108761YA (https=)
TW (1) TWI901581B (https=)
WO (1) WO2020182974A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022057910A1 (en) * 2020-09-17 2022-03-24 I-Mab Biopharma Co., Ltd Combination therapies targeting c5ar and pd-1/pd-l1 pathways
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US8071096B2 (en) * 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
MX2010005603A (es) * 2007-11-26 2010-08-02 Bayer Schering Pharma Ag Anticuerpos antimesotelina y usos de los mismos.
RU2010138612A (ru) 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
MX340696B (es) * 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
DK3424953T3 (en) * 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
JP2016523829A (ja) * 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
ES2736500T3 (es) 2014-06-18 2020-01-02 Morphosys Ag Proteínas de fusión y usos de las mismas
TWI786132B (zh) 2017-06-23 2022-12-11 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療

Also Published As

Publication number Publication date
JP7617012B2 (ja) 2025-01-17
JP7842914B2 (ja) 2026-04-08
TW202041535A (zh) 2020-11-16
NZ778810A (en) 2025-10-31
CN113574072A (zh) 2021-10-29
EP3938393A1 (en) 2022-01-19
CN113574072B (zh) 2023-12-12
WO2020182974A1 (en) 2020-09-17
US20240400657A1 (en) 2024-12-05
SG11202108761YA (en) 2021-09-29
JP2022524449A (ja) 2022-05-02
JP2025069140A (ja) 2025-04-30
IL286238A (en) 2021-10-31
BR112021017860A2 (pt) 2021-12-07
TWI901581B (zh) 2025-10-21
US20240018225A1 (en) 2024-01-18
KR20210141988A (ko) 2021-11-23
US12018072B2 (en) 2024-06-25
MX2021011040A (es) 2021-12-10
CA3132771A1 (en) 2020-09-17
US20220135658A1 (en) 2022-05-05
MA55285A (fr) 2022-01-19

Similar Documents

Publication Publication Date Title
JP7247238B2 (ja) イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ－８に結合する抗体、およびその使用
US12410256B2 (en) Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
JP7403505B2 (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
US12018072B2 (en) Antibodies specific for human complement C5A receptor (C5AR)
KR102257154B1 (ko) Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
CA2993423C (en) Il-8-binding antibodies and uses thereof
US20250059288A1 (en) Antibodies targeting ccr2
RU2823245C2 (ru) Антитела, нацеливающиеся на C5aR
CA3220167A1 (en) Anti-trem-1 antibodies
HK40061359A (en) Antibodies targeting c5ar
HK40061359B (zh) 靶向c5ar的抗体
HK40111251A (zh) 靶向ccr2的抗体

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO MORPHOSYS GMBH